US Software AI Wave Q2 2026: Expensify +250%, Five9 AI +78%, Microvision LiDAR +650%

The Quick Take

• Expensify (EXFY) narrows losses and raises full-year guidance as its AI-powered New Expensify product surges 250%, displacing legacy expense management with AI-native architecture
• Five9 (FIVN) beats Q2 revenue guidance with AI contact center revenue growing 78%, raising its full-year AI outlook to at least 78% growth as enterprise deployments accelerate
• Microvision (MVIS) reports 650% revenue surge in Q2 2026 on LiDAR commercialization; Alarm.com posts SaaS margin expansion of 115 basis points; AVITA Medical raises FY guidance to $86-89M

US software and AI-adjacent technology companies reported broadly strong Q2 2026 results, with AI-native products and services showing the highest growth rates across the cohort. The results confirm a structural shift in enterprise software spending: buyers are prioritizing AI-augmented platforms over legacy tools, even when AI-native alternatives carry higher deployment complexity.

Expensify Inc (EXFY) narrowed its operating losses and raised its full-year guidance, driven by its AI-powered New Expensify product which surged 250% in adoption. The platform reimagines corporate expense management as an AI-native workflow, automating receipt capture, categorization, and approval routing in ways that legacy tools like Concur cannot replicate natively. Five9 Inc (FIVN) beat Q2 revenue guidance with AI contact center revenue growing 78% year-over-year, raising its full-year AI outlook as large enterprise customers accelerated deployments of AI-assisted agent and customer self-service tools.

Microvision Inc (MVIS) reported a 650% revenue surge driven by LiDAR commercialization contracts — a company-transforming development that marks the transition from R&D spending to commercial revenue recognition. Alarm.com Holdings (ALRM) delivered 115 basis points of EBITDA margin expansion, while its commercial and EnergyHub segments drove diversified growth beyond its core residential security market. AVITA Medical (AVHHL) raised its full-year 2026 revenue guidance to $86-$89 million and expects to reach cash flow breakeven by Q3, demonstrating the scaling dynamics of its regenerative medicine wound care platform. Across the 12 companies, AI adoption and recurring SaaS metrics were the strongest performance differentiators.

Synthesized from 12 sources.